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ABSTRACT
Oligosaccharides are the third most abundant com-
ponent in human milk. It is widely accepted that they 
play several important protective, physiological, and 
biological roles, including selective growth stimulation 
of beneficial gut microbiota, inhibition of pathogen ad-
hesion, and immune modulation. However, until recent-
ly, very few commercial products on the market have 
capitalized on these functions. This is mainly because 
the quantities of human milk oligosaccharides required 
for clinical trials have been unavailable. Recently, clini-
cal studies have tested the potential beneficial effects 
of feeding infants formula containing 2′-fucosyllactose, 
which is the most abundant oligosaccharide in human 
milk. These studies have opened this field for further 
well-designed studies, which are required to fully un-
derstand the role of human milk oligosaccharides. 
However, one of the most striking features of human 
milk is its diversity of oligosaccharides, with over 200 
identified to date. It may be that a mixture of oligosac-
charides is even more beneficial to infants than a single 
structure. For this reason, the milk of domestic animals 
has become a focal point in recent years as an alterna-
tive source of complex oligosaccharides with associated 
biological activity. This review will focus specifically 
on free oligosaccharides found in bovine and caprine 
milk and the biological roles associated with such 
structures. These dairy streams are ideal sources of oli-
gosaccharides, given their wide availability and use in 
so many regularly consumed dairy products. The aim 
of this review was to provide an overview of research 
into the functional role of bovine and caprine milk oli-
gosaccharides in host–microbial interactions in the gut 
and provide current knowledge related to the isolation 
of oligosaccharides as ingredients for incorporation in 
functional or medical foods.
Key words: animal milk, oligosaccharides, gut health, 
host–microbe interactions
INTRODUCTION
In recent times, awareness has been growing that 
breast milk beneficially supports the infant immune 
system (Cacho and Lawrence, 2017) and modulates 
microbiota composition during the first months of life. 
Among the various bioactive components in breast 
milk, human milk oligosaccharides (HMO) are sug-
gested to play a leading role (Ayechu-Muruzabal et al., 
2018; Xiao et al., 2019). Human milk oligosaccharides 
are made of linear or branched monosaccharides, such 
as galactose, glucose, N-acetylglucosamine, fucose, and 
sialic acid, varying in size from 3 to 22 monosaccharide 
units (German et al., 2008; Bode, 2012). In contrast to 
the milk of other mammals, human breast milk con-
tains a very high amount and a structurally diverse set 
of oligosaccharides that even exceeds the protein con-
tent of breast milk (Zivkovic et al., 2011; Bode, 2012; 
Triantis et al., 2018). Indeed, HMO constitute the third 
largest solid component of human milk after lactose 
and lipids (Kunz et al., 2000; Thurl et al., 2010). Table 
1 outlines the overall concentrations of oligosaccharides 
found in human and dairy animal milks and highlights 
the major oligosaccharide structures common between 
these milks.
Surprisingly, HMO offer no direct nutritional value 
to infants and involve only minor absorption across the 
intestinal wall, with approximately 0.1 and 4% detect-
able in plasma and urine, respectively (Goehring et al., 
2014; Dotz et al., 2015; Underwood et al., 2015). They 
are now recognized to have various additional benefits 
for the developing infant. They are favored substrates 
for several species of gut bacteria and act as prebiot-
ics, promoting the growth of a beneficial microflora 
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and shaping the gut microbiome, in turn beneficially 
influencing immune responses (Doherty et al., 2018). 
Fermentation products, such as short-chain fatty acids 
generated from gut bacteria breaking down HMO, are 
immunoregulating and serve as nutrients for beneficial 
gut commensals and epithelial cells (Trompette et 
al., 2014). Human milk oligosaccharides also directly 
modulate host epithelial responses, resulting in reduced 
binding of pathogens to the gut epithelium. In addition, 
HMO act as decoy receptors, inhibiting the binding of 
enteric pathogens to prevent infection and subsequent 
illness (Smilowitz et al., 2014). Furthermore, HMO 
provide a selective advantage for colonization by fa-
vorable bacteria, in turn inhibiting the colonization of 
pathogenic species. Human milk oligosaccharides and 
their metabolic products, such as sialic acid, also play 
a role in brain development, neural transmission, and 
synaptogenesis (Bienenstock et al., 2013; Jacobi et al., 
2016).
However, the protective effects ascribed to HMO are 
for the most part unavailable to formula-fed infants, 
with the exception of 2′-fucosyllactose and lacto-N-
neotetraose, which have been added to some formulas 
recently (European Union, 2017; Puccio et al., 2017). 
Despite this advancement, the complexity of HMO 
makes it almost impossible for their associated func-
tions to be duplicated in formulas. Infant milk formulas 
are based on bovine milk and to a lesser extent caprine 
milk, which contain lower concentrations of oligosac-
charides (~0.03 and 0.30 g/L, respectively; Kunz et al., 
2000; Martinez-Ferez et al., 2006a). However, at least 
10 bovine milk oligosaccharides (BMO) and 9 caprine 
milk oligosaccharides (CMO) share the same structure 
as certain HMO (outlined in Table 1), which could im-
ply common functionalities (Barile et al., 2009; Silanik-
ove et al., 2010; Mariño et al., 2011; Robinson, 2019). 
Therefore, value may lie in extracting and concentrat-
ing oligosaccharides from domestic animal milks with a 
view to adding them as an active ingredient to infant 
formulas. This review highlights recent studies from 
our group and others that demonstrate novel bioactivi-
ties associated with BMO and CMO, with a particular 
focus on their influence on host–microbial interactions 
in the gut. The review also provides an overview of cur-
rent developments in industrial-scale processes for milk 
oligosaccharide production from dairy streams.
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Total in colostrum milk 20–23 1.0 0.4–1.35
Total in mature milk 12–15 0.03–0.06 0.25–0.3
2′-Fucosyllactose (2′-FL) 1.88–4.9 Trace Trace
3′-Fucosyllactose (3′-FL) 0.25–0.86 Trace Trace
Lacto-N-tetraose (LNT) 0.5–1.5 Trace Trace
Lacto-N-neotetraose (LNnT) 0.04–0.2 Trace —
Lacto-N-fucopentaose I (LNFPI) 1.2–1.7 — —
Lacto-N-fucopentaose II (LNFPII) 0.3–1.0 — —
Lacto-N-fucopentaose III (LNFPIII) 0.01–0.2 — Trace
3′-Sialyllactose (3′-SL) 0.1–0.3 0.035–0.119 0.03–0.05
6′-Sialyllactose (6′-SL) 0.3–0.5 0.014–0.088 0.05–0.07
Sialyllacto-N-tetraose (a) (LSTa) 0.03–0.2 Trace —
Sialyllacto-N-tetraose (b) (LSTb) 0.01–0.16 — —
Sialyllacto-N-tetraose (c) (LSTc) 0.1–0.6 Trace —
6′-Sialyllactosamine (6′ SLN) — 0.009–0.176 Trace
Disialyllactose (DSL) — 0.002–0.07 0.001–0.005
Disialyllactose-N-tetraose (DSLNT) 0.2–0.6 Trace —
α-3′-Galactosyllactose (α3′-GL) — Trace 0.03–0.05
β-3′-Galactosyllactose (β3′-GL) Trace Trace 0.03
β-4′-Galactosyllactose (4′-GL) Trace — —
β-6′-Galactosyllactose (6′-GL) 0.002 Trace Trace
α-3′-N-acetylgalactosaminyllactose (α-3′-GalNAcL) — 0.003–0.065 Trace
Lacto-N-difucohexaose I (LNDFH-I) 0.58 — —
Lacto-N-neohexaose (LNnH) Trace — —
Lacto-N-hexaose (LNH) 0.13 — 0.001–0.005
6′-N-Acetyl-glucosaminyl-lactose (NAL) — Trace 0.02–0.04
1The ranges shown reflect differences due to variations in the analytical methods used in the different studies, 
and they reflect changes in abundance over lactation (i.e., from colostrum to mature milk). Compiled data 
are from Gopal and Gill (2000); Kunz et al. (2000); Wang et al. (2001); Nakamura et al. (2003); Nakamura 
and Urashima (2004); Uemura et al. (2009); Fong et al. (2011); Oliveira et al. (2012); Aldredge et al. (2013); 
Meyrand et al. (2013); Albrecht et al. (2014); Oliveira et al. (2015); Austin et al. (2016); Sprenger et al., (2017); 
Ma et al. (2018); Samuel et al., (2019); Sousa et al. (2019b); Tonon et al. (2019).
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MILK OLIGOSACCHARIDE STRUCTURE
Milk oligosaccharides have a lactose core and are 
enzymatically elongated by β1–3 and β1–6 linkages to 
units of lacto-N-biose and N-acetylactosamine, respec-
tively. Milk oligosaccharides are further elongated by 
the addition of fucose and sialic acid at the terminal 
positions (Figueroa-Lozano and de Vos, 2019). A large 
number (100 to 200) of different HMO can be found in 
individual milk samples (Totten et al., 2012; Urashima 
et al., 2018). Concentrations in mature human milk 
ranges from 12 to 15 g/L, but relative proportions 
and amounts vary depending on the lactating stage, 
Lewis blood group, secretor status, feed practices, and 
environmental factors (Bode, 2012; Azad et al., 2018; 
Zúñiga et al., 2018; Seppo et al., 2019). Among these 
elements, the individual maternal genetic disposition 
has a large effect on the HMO profile of human milk, 
particularly the individual expression pattern of Lewis 
and secretor gene alleles that encode different fucosyl-
transferases.
The significant difference between human and animal 
milk oligosaccharide pools is that human milk contains 
high levels of fucosylated oligosaccharides, accounting 
for approximately 70% of oligosaccharides in human 
milk, with high levels of 2′-fucosyllactose detected (e.g., 
4.65 g/L; Chaturvedi et al., 2001; Asakuma et al., 2008; 
Marriage et al., 2015). Another difference between the 
milks is the predominance of type 1 oligosaccharides 
in human milk (Urashima et al., 2012, 2013, 2016). In 
contrast, animal milk counterparts contain higher levels 
of sialylated oligosaccharides containing N-acetylneur-
aminic acid or N-glycolylneuraminic acid (Urashima et 
al., 2001, 2013). Added to this, only about 40 BMO and 
CMO structures have been identified to date (Tao et 
al., 2008; Albrecht et al., 2014). However, despite these 
differences, structurally identical oligosaccharides are 
found in human and animal milk oligosaccharide pools 
(Table 1). Indeed, many of these individual structures 
have been identified as having specific biological activi-
ties, so it is likely these structures may offer the same 
physiological benefits as oligosaccharides derived from 
human milk (Vicaretti et al., 2018).
THE ROLE OF MILK OLIGOSACCHARIDES  
IN HOST–MICROBE INTERACTIONS
The diverse functions of milk oligosaccharides on the 
gut microbiome are as follows: they act as prebiotics 
and stimulate the growth of beneficial microbes; they 
promote the colonization of beneficial microbes; they 
exert direct and indirect defense mechanisms against 
pathogens and protect infants from infections; and they 
act as signaling molecules and interact directly with 
host cells (Figure 1). For insights into how milk oligo-
saccharides affect immune system development, which 
is outside the scope of this article, we refer the reader to 
some excellent recent reviews (Plaza-Díaz et al., 2018; 
Triantis et al., 2018).
Role of Milk Oligosaccharides as Prebiotics
The human gut lacks glycoside hydrolases and intes-
tinal membrane transporters, which can degrade milk 
oligosaccharides; therefore, HMO are not digested in 
the upper part of the gastrointestinal tract of infants 
(Engfer et al., 2000; German et al., 2008). As a result, 
the majority of HMO reach the colon, where they act 
as a substrate for specific bacteria, influencing the com-
position of the gastrointestinal microbiota (Garrido et 
al., 2011). Human milk oligosaccharides are specifically 
known to influence populations of beneficial bacteria, 
such as Bifidobacterium (Garrido et al., 2011; Akker-
man et al., 2019), a dominant species in the intestine of 
breastfed infants. These bacteria have the ability to use 
HMO with dedicated enzymes (glycoside hydrolases), 
transporters, and other molecules that contribute to 
degradation (Goh and Klaenhammer, 2015). Genomic 
analysis of a prototypical infant-derived bifidobacteria, 
Bifidobacterium longum ssp. infantis, which grows well 
on HMO, revealed a single cluster of genes coding for 
enzymes dedicated to the degradation of HMO, sug-
gesting co-evolution of this strain with human milk 
(Ward et al., 2006; Sela and Mills, 2010). Analysis of 
other infant strains of Bifidobacterium longum ssp. 
longum, Bifidobacterium bifidum, and Bifidobacterium 
breve, which also grow on HMO (LoCascio et al., 2009; 
Asakuma et al., 2011; Ruiz-Moyano et al., 2013), were 
shown to also possess specific milk glycan transport-
ers and glycosyl hydrolases linked to milk glycan usage 
(Garrido et al., 2013; Ruiz-Moyano et al., 2013; Matsuki 
et al., 2016; Sakanaka et al., 2019; Zabel et al., 2019). 
The role of HMO as prebiotics is well characterized and 
we refer the reader to many excellent reviews on this 
topic (Marcobal and Sonnenburg, 2012; Moossavi et al., 
2018; Reverri et al., 2018; Zúñiga et al., 2018).
The use of BMO as prebiotics is less well investigat-
ed; only a limited number of in vitro studies have been 
documented. A recent example is a study by Jakobsen 
et al. (2019), in which proton nuclear magnetic reso-
nance metabolomics and molecular biology methods 
were combined to quantify bacteria and compare the 
effect of BMO and synthetic galacto-oligosaccharides 
on mono- and co-cultures of 8 major bacteria related to 
a healthy infant microbiome. The results revealed that 
BMO treatments supported the growth of B. longum 
ssp. longum and Parabacteroides distasonis, while at 
the same time inhibiting the growth of Clostridium 
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perfringens and Escherichia coli. Perdijk et al. (2019) 
investigated the effect of sialyllactose (isolated from 
bovine milk) on microbiota composition and short-
chain fatty acid production using in vitro fecal batch 
cultures. Sialyllactose resulted in a distinct modulation 
of microbiota composition, promoting the outgrowth 
of Bacteroides and bifidobacteria, which resulted in 
distinct changes in short-chain fatty acid production 
profiles.
Caprine milk oligosaccharides have also been shown 
to have prebiotic characteristics in vitro (Oliveira et 
al., 2012). Increased numbers of Bifidobacterium spp. in 
the presence of CMO have been demonstrated using in 
vitro fermentation models (Thum et al., 2015; Barnett 
et al., 2018). A recent study by Leong et al. (2019) 
examined the presence of naturally occurring oligosac-
charides in commercial caprine milk–based stage 1 and 
stage 2 infant formulas and their prebiotic properties. 
Fourteen quantifiable oligosaccharides in caprine milk–
based infant formula were detectable by LC/MS. These 
oligosaccharides significantly enhanced the growth of 
bifidobacteria and lactobacilli in vitro.
The ability of BMO to modulate the gut microbiota 
in vivo has been the subject of several recent stud-
ies. Meli et al. (2014) revealed positive trends in stool 
bacterial counts in infants fed BMO-supplemented 
formulas. The BMO in this case were generated from 
whey permeate. In a randomized controlled double-
blind clinical trial, Simeoni et al. (2016) tested the ef-
fect of feeding a formula supplemented with a mixture 
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Figure 1. Schematic overview of the suggested mechanisms of action of milk oligosaccharides in the human intestine. Here, oligosaccharides 
may serve as prebiotics, promote the colonization of bifidobacteria, act as decoys for pathogens, and modify epithelial glycan receptor expression.
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of BMO generated from whey permeate, containing 
galacto-oligosaccharides and 3′- and 6′-sialyllactose, 
and the probiotic Bifidobacterium animalis ssp. lactis 
strain CNCM I-3446. The same formula without ad-
dition of the prebiotic–probiotic blend was used in the 
control group. Breastfed infants served as the reference 
group. The test formula with the prebiotic–probiotic 
blend was well tolerated, and a strong bifidogenic ef-
fect was observed. The control group, but not the test 
group, differed from the breastfed reference group, 
showing a higher fecal pH and a significantly higher 
diversity in the fecal microbiota. In the test group, the 
probiotic B. animalis ssp. lactis increased by 100-fold in 
feces and was detected in all supplemented infants. The 
BMO stimulated a marked shift to a Bifidobacterium-
dominated fecal microbiota via increases in endogenous 
bifidobacteria (e.g., B. longum, B. breve, B. bifidum, Bi-
fidobacterium pseudocatenulatum; Simeoni et al., 2016).
In another study, germ-free mice and newborn piglets 
were colonized with a consortium of cultured bacterial 
strains isolated from the fecal microbiota of a severely 
stunted Malawian infant and fed a representative Ma-
lawian diet with or without the addition of sialylated 
BMO (Charbonneau et al., 2016). The results demon-
strated that this BMO preparation produced a micro-
biota-dependent promotion of growth and metabolic 
changes indicative of improved nutrient use in both host 
species. A study by Boudry et al. (2017) investigated 
whether a combination of dietary BMO and B. longum 
ssp. infantis could reverse the gut microbial dysbiosis 
and altered gut permeability induced by ingestion of 
the Western diet. Male C57BL/6 mice were fed a West-
ern diet (40% fat/kcal) or normal chow (14% fat/kcal) 
for 7 wk. During the final 2 wk of the study, the diet 
of a subgroup of mice fed the Western diet was supple-
mented with BMO (7% wt/wt). Supplementation with 
BMO normalized the cecal and colonic microbiota, and 
the authors observed an increased abundance of Lacto-
bacillus compared with the mice fed the Western diet 
alone and the control (chow-fed) mice. In addition, 
restoration of Allobaculum and Ruminococcus levels in 
the BMO group was observed, which was comparable 
to that of the control group. A similar study by Hamil-
ton et al. (2017) investigated C57BL/6 mice that were 
fed a control diet, a high-fat diet (40% fat/kcal), or a 
high-fat diet and 6%/kg BMO for 1, 3, or 6 wk. Gut 
microbiota and intestinal permeability were assessed 
in the ileum, cecum, and colon. The BMO completely 
abolished the increase in paracellular and transcellular 
permeability in the small and large intestine induced by 
the high-fat diet, and increased the abundance of Bifi-
dobacterium and Lactobacillus in the ileum.
Using preterm piglets, Obelitz-Ryom et al. (2018) 
investigated the effects of bovine milk supplements 
enriched with oligosaccharides to improve gut develop-
ment and colonization. Supplements with BMO were 
well tolerated, but did not improve gut maturation 
or clinical outcomes in artificially reared preterm pig-
lets. The authors concluded that immaturity at birth, 
coupled with artificial rearing, may render the neonate 
unresponsive to the gut-protective effects of milk oli-
gosaccharides. A study by Jena et al. (2018) examined 
the effects of BMO and B. longum ssp. infantis in pre-
venting nonalcoholic steatohepatitis in bile acid recep-
tor FXR (farnesoid × receptor) knockout mice fed a 
Western diet. The authors found that BMO increased 
the abundance of butyrate-generating bacteria, which 
has a beneficial effect in nonalcoholic steatohepatitis 
treatment. In a recent study, Cowardin et al. (2019) 
colonized germ-free mice with cultured bacterial strains 
from a 6-mo-old stunted infant and fed the mice a 
diet supplemented with bovine sialylated milk oligo-
saccharides. Although this study was focused on bone 
biology, the diet was associated with BMO-dependent 
and microbiota-dependent increases in cecal levels of 
succinate, increased numbers of small intestinal tuft 
cells, and evidence for the activation of a succinate-
induced tuft cell signaling pathway linked to T helper 
(Th)2 immune responses. In contrast, similar studies 
on CMO are limited. Thum et al. (2016) found that 
consumption of CMO by mice during gestation and lac-
tation improved the development of their pups, and the 
relative abundance of bifidobacteria and butyric acid in 
the colon at weaning. Overall, these studies highlight 
the potential of domestic animal milks as a source of 
oligosaccharides that can aid in shaping the enrichment 
of a protective intestinal microbiota.
Effect of Milk Oligosaccharides on the Colonization 
of Bifidobacteria
Bifidobacteria are associated with several health-
related benefits for the host, including inhibiting the 
growth of pathogenic organisms, modulating mucosal 
barrier function, and promoting appropriate immu-
nological and inflammatory responses (Gareau et al., 
2010; Buffie and Pamer, 2013). To exert a beneficial 
effect, a sufficient population of bifidobacteria must 
colonize the host and initially adhere to intestinal cells 
(Westermann et al., 2016). Our group has recently 
found that oligosaccharides from domestic animal milks 
may contribute not only to the selective growth of bi-
fidobacteria but also to their specific adhesive ability. 
Kavanaugh et al. (2013) showed that treatment of B. 
longum ssp. infantis ATCC 15697 with a mixture of 
3′- and 6′-sialyllactose found in human and domestic 
animal milks substantially increased bacterial adhe-
sion (up to 9.8-fold) to human HT-29 intestinal cells 
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in vitro. Moreover, transcriptomic analysis revealed 
that the increased adherence phenotype of the strain 
resulting from exposure to the oligosaccharide is likely 
multifaceted, involving transcription factors, chaperone 
proteins, adhesion-related proteins, and a glycoside 
hydrolase (Kavanaugh et al., 2013). More recently, 
our group found that CMO also resulted in increased 
adhesion (8.3-fold) of B. longum ssp. infantis to HT-29 
intestinal cells when used at physiological concentra-
tions (Quinn et al., 2018).
Bovine milk components may also modulate intes-
tinal epithelial cell surface glycans, thereby reducing 
or increasing the prevalence of attachment sites for 
bacteria (Angeloni et al., 2005). In a recent study by 
our group, HT-29 intestinal cells were exposed to a 
bovine colostrum fraction rich in free oligosaccharides 
(Morrin et al., 2019a). The adherence of several com-
mensal bacteria (comprising mainly bifidobacteria) to 
the intestinal cells was significantly enhanced (up to 
52-fold) for all strains tested, which spanned species 
that are found across the human lifespan. Importantly, 
the changes to the HT-29 cell surface did not support 
enhanced adhesion of the enteric pathogens tested. The 
gene expression profile of the HT-29 cells following 
treatment with the colostrum fraction was evaluated 
by microarray analysis (Morrin et al., 2019a). Many 
so-called glyco-genes (glycosyltransferases and genes 
involved in the complex biosynthetic pathways of gly-
cans) were found to be differentially regulated, suggest-
ing modulation of the enzymatic addition of sugars to 
glycoconjugate proteins. Changes in the glycosylation 
pattern of the intestinal cells upon exposure to the 
colostrum fraction were also demonstrated through the 
use of lectin arrays (Morrin et al., 2019b). These stud-
ies highlight the potential of bovine milk components 
as functional ingredients that could increase the attach-
ment of health-promoting bacteria in the gut, which 
may be important to individuals with lower counts of 
such bacteria.
Protective Role of Milk Oligosaccharides Against 
Pathogens and Infection
Milk oligosaccharides are considered to be soluble re-
ceptor analogs of epithelial cell surface carbohydrates, 
because they are generated from similar enzymes (Kunz 
et al., 2000; Smilowitz et al., 2014). These structures 
display structural homology to host cell receptors and 
thus function as receptor decoys that pathogens can 
bind to instead of the host. Oligosaccharides can also 
inhibit pathogens by competitive binding with the host 
cell surface receptor (Morrow et al., 2005). An expan-
sive literature exists describing the action of HMO 
against a variety of pathogens (Hickey, 2012; Li et al., 
2014; Manthey et al., 2014; Laucirica et al., 2017), but 
information on the role of oligosaccharides from domes-
tic animal milks in preventing infection is more limited. 
Examples exist of 3′ and 6′- sialyllactose being used 
as anti-infectives. Mysore et al. (1999) investigated the 
effect of 3′-sialyllactose on colonization of Helicobacter 
pylori in rhesus monkeys. Of the 6 monkeys given the 
milk oligosaccharide, 2 were cured permanently, 1 was 
transiently cleared, and 3 animals remained persistently 
colonized, suggesting that these oligosaccharides can 
cure or decrease H. pylori colonization in some cases. 
Martín et al. (2002) investigated whether BMO had 
the potential to protect against 7 enterotoxigenic E. 
coli strains isolated from diarrheic calves. Inhibition of 
hemagglutination in the presence of oligosaccharides 
was used as an indicator of interaction between the 
oligosaccharides and bacterial adhesins. Mid-lactation 
milk oligosaccharides, in particular, proved to be the 
most efficient at inhibiting hemagglutination.
Coppa et al. (2006) included a Salmonella fyris strain 
in their study on inhibition of pathogen adhesion to 
Caco-2 cells. The study showed that 6′-sialyllactose 
had an anti-adhesive effect on S. fyris. In a study by 
our group, we examined oligosaccharides isolated and 
purified from the colostrum of Holstein-Friesians for 
anti-infective activity against a highly invasive strain 
of Campylobacter jejuni (Lane et al., 2012). During 
our initial studies, we structurally defined 37 bovine 
colostrum oligosaccharides (BCO) in our sample by 
hydrophilic interaction liquid chromatography (HIL-
IC)–HPLC coupled with exoglycosidase digests and of-
fline mass spectroscopy (Mariño et al., 2011). We then 
examined the effect of the BCO on C. jejuni adhesion 
to, invasion of, and translocation of intestinal HT-29 
cells. We found that the BCO dramatically reduced the 
cellular invasion and translocation of C. jejuni, in a 
concentration-dependent manner. Periodate treatment 
of the BCO before inhibition studies resulted in a loss of 
anti-infective activity of the oligosaccharides, suggest-
ing a direct oligosaccharide–bacterial interaction. We 
found that 5 mg/mL BCO, which is similar to physi-
ological concentrations of HMO in breastmilk, dramati-
cally decreased the level of internalized bacteria by up 
to 50% compared with the control (Lane et al., 2012). 
Maldonado-Gomez et al. (2015) also demonstrated that 
BCO could prevent the adhesion of enteropathogenic E. 
coli, Cronobacter sakazakii and Salmonella enterica se-
rovar Typhimurium to HEp-2 cell monolayers cultured 
in vitro (Maldonado-Gomez et al., 2015). Recently, 
neutral and acidic oligosaccharides isolated from cap-
rine milk and bovine colostrum were compared for their 
potency to inhibit the adhesion of S. enterica IID604 to 
Caco-2 cells using HMO as a positive control (Urakami 
et al., 2018). Both the CMO and BCO inhibited the ad-
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hesion of S. enterica to Caco-2 cells at concentrations 
ranging from 2.5 to 5.0 mg/mL. The ability of CMO 
to prevent the adhesion of E. coli NCTC 10418 and 
a Salmonella Typhimurium isolate to Caco-2 cells was 
also recently demonstrated (Leong et al., 2019). These 
studies build a strong case for exploring the possibility 
of using oligosaccharides sourced from dairy streams as 
potential anti-infectives.
Effect of Milk Oligosaccharides on Intestinal 
Epithelial Cells
Intestinal health and barrier function are considered 
to be the first line of defense in the gastrointestinal 
tract (Holscher et al., 2014). In this respect, HMO can 
modify host–microbe interactions by affecting epithe-
lial cell turnover (Kuntz et al., 2008) and intestinal 
glycocalyx formation (Angeloni et al., 2005; Straub-
inger et al., 2010; Kong et al., 2019). The HMO are 
able to directly affect the intestinal cell response by 
reducing the cell growth and by inducing differentia-
tion and apoptosis (Kuntz et al., 2008). They have also 
been reported to increase intestinal cell maturation 
(Holscher et al., 2017). Considering the consequences 
of pathogen invasion and the advantages of commensal 
colonization, it favors the gastrointestinal environment, 
and ultimately the host, to possess a means by which 
to rapidly adapt to possible threats while maintain-
ing a hospitable environment for beneficial organisms. 
Some evidence shows that 3′-sialylactose, one of the 
main oligosaccharides of both human and domestic 
milks, may modulate intestinal epithelial cell surface 
glycans, thereby reducing or increasing the prevalence 
of attachment sites for bacteria (Angeloni et al., 2005). 
Exposure of 3′-sialylactose to Caco-2 cells altered the 
glycan profile of the cell surface. The expression of the 
sialyltransferases ST3Gal1, 2, and 4 were reduced, but 
ST3Gal3, 5, and 6 were unaffected by 3′-sialylactose. 
The subsequent reduction in α-2,3– and α-2,6–linked 
sialic acid coincided with reduced adhesion of entero-
pathogenic E. coli to the cells (Angeloni et al., 2005). 
These results suggest that 3′-sialyllactose modulates 
the intestinal cell surface glycome via differential regu-
lation of genes associated with glycosylation in much 
the same way as described by our group (Morrin et al., 
2019a,b). Interestingly, recent studies examining the 
effect of a CMO on barrier function of epithelial cell 
co-cultures found that the CMO at the maximum con-
centration tested (4.0 mg/mL) enhanced transepithelial 
electrical resistance, mucin gene expression, and mucin 
protein abundance in epithelial co-cultures, all of which 
are essential components of intestinal barrier function 
(Barnett et al., 2016, 2018). Collectively, these findings 
suggest that milk components can directly modulate 
the intestinal cell surface and potentially alter the gly-
cosylation state of the cells, which in turn may facilitate 
the adherence of distinct communities of bacteria.
INDUSTRIAL-SCALE STRATEGIES TO PRODUCE 
DAIRY OLIGOSACCHARIDES
Considering the wide availability of dairy side 
streams from which oligosaccharides can be isolated, 
BMO and CMO show promise as future therapeutics 
that could be used to provide HMO-associated health 
benefits to infants and adults on a large scale. Whey, 
the liquid part of milk that separates from the curd 
during cheese production, is a particularly attractive 
source of oligosaccharides. This stream is rich in lactose 
and protein, but has a high biochemical and chemical 
oxygen demand, making it costly to dispose of within 
environmental regulations (Peters, 2005). Martinez-
Ferez et al. (2006b) were among the first to describe the 
use of membrane technology for the isolation of oligo-
saccharides from animal milk, in this case pasteurized 
skimmed caprine milk. A 2-stage tangential filtration 
process was used, and at the end of the process, 80% 
of the oligosaccharides had been obtained in the final 
retentate. Oliveira et al. (2012) also used ultrafiltration 
to remove proteins and fat globules from caprine whey, 
and then further processed the ultrafiltered permeate 
using a 1-kDa “tight” ultrafiltration membrane. The 
final retentate was fractionated by preparative scale 
molecular size exclusion chromatography to yield 28 
oligosaccharide-rich fractions.
Ultrafiltered whey permeate is disposed of at a cost 
to the whey processor or used to produce food-grade 
lactose by crystallization (Mehra et al., 2014). Milk 
oligosaccharides pass through the ultrafiltration mem-
branes, ending up in the whey permeate (Barile et al., 
2009; Mehra et al., 2014). The liquid that is separated 
from lactose crystals is known as mother liquor, and is 
usually disposed of in sewage plants or sold as animal 
feed. A study by Mehra et al. (2014) resulted in the 
concentration of BMO from mother liquor using mem-
brane filtration technology. A combination of HPLC 
and accurate MS allowed the identification of optimal 
processing conditions, which resulted in the produc-
tion of kilogram amounts of BMO-enriched powders. 
Among the BMO identified in the powder, 18 had high 
molecular weights and corresponded in size to the most 
abundant oligosaccharides present in human milk. In-
terestingly, 6 oligosaccharides contained fucose, which 
is rarely detected in bovine milk (Mehra et al., 2014).
More commonly, a combination of lactose hydrolysis 
and membrane filtration is used to isolate oligosaccha-
rides from milk to increase purity. Recently, de Moura 
Bell et al. (2018) developed a novel pilot-scale approach 
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for the recovery of highly pure oligosaccharides, from 
colostral bovine whey permeate. Because the concen-
tration of BMO in colostrum is much higher than in 
mature milk (Nakamura et al., 2003; Fong et al., 2011), 
it represents an available source from which to separate 
BMO on a large scale. The method described by de 
Moura Bell et al. (2018) relies on the integration of 
optimized processing conditions that favor maximum 
lactose hydrolysis and monosaccharide fermentation 
before concentrating the oligosaccharides by selec-
tive membrane filtration. Upon complete lactose hy-
drolysis and fermentation of the monosaccharides by 
yeast, nanofiltration of fermented whey permeate from 
colostrum enabled the recovery of 95% of the oligosac-
charides at high purity (de Moura Bell et al., 2018). 
This processing strategy has also been applied to the 
recovery of CMO at a pilot scale, with a 75% recovery 
of oligosaccharides (Aquino et al., 2017), and recently 
further optimized in terms of enzymatic hydrolysis 
(Thum et al., 2019). Overall, processing conditions us-
ing temperatures ≤40°C and an enzyme concentration 
of ≤0.25% resulted in a higher preservation or forma-
tion of caprine whey oligosaccharides. Martín-Ortiz et 
al. (2019) were also successful in the selective removal 
of lactose, and the resulting glucose and galactose, from 
pooled caprine colostrum using a biotechnological pro-
cedure based on the combined use of β-galactosidase 
from Kluyveromyces lactis (optimal conditions: 0.68 U/
mL enzyme, 37°C, 15 min, and pH 7) and yeast from 
Saccharomyces cerevisiae (optimal conditions: 37°C, 24 
h).
Another recent study investigated the characteriza-
tion and concentration of oligosaccharides naturally 
present in caprine cheese whey obtained from 2 types of 
caprine milk (Sousa et al., 2019a). The caprine cheese 
whey was processed by a 2-step cross-flow filtration 
process and a HILIC–UPLC coupled to high-definition 
mass spectrometry. A quadrupole time-of-flight (HILIC 
UPLC-HDMS-Q-TOF) method was used to identify and 
measure oligosaccharides in the samples. A final prod-
uct with recovery of 63 to 96% of oligosaccharides was 
obtained compared with the original whey. Although 
membrane filtration is the most commonly investigated 
technique for producing dairy-derived oligosaccharides 
on a large scale, our group has had some recent success 
using scalable chromatography approaches to produce 
bovine oligosaccharides from whey streams (European 
Patent Application No. EP18214230.7), an area we 
continue to explore.
CONCLUSIONS
Because HMO are supplied through breastfeeding, 
their valuable effects are largely lost to formula-fed in-
fants. Substitution of infant formula with dairy-derived 
oligosaccharides to impart HMO functions is a potential 
solution, in addition to the benefits already observed 
by supplementation of formulas with 2′-fucosyllactose. 
Oligosaccharides generated from bovine or caprine milk 
may have many applications in foods (e.g., in infant 
milk formula, infant foods, follow-on formula, bever-
ages, and fermented milks). It may be that a mixture 
of oligosaccharides such as those generated from dairy 
streams may be even more beneficial to infants than 
individual oligosaccharides. A mixture could better rep-
resent the great variety of chemical structures found in 
human milk and as such allow more than one function. 
More studies are required to investigate the different in 
vivo actions of such ingredients on intestinal modula-
tion and their technological implications when added to 
formula. Future clinical research should be directed at 
addressing the following questions: which specific milk 
oligosaccharides in the BMO and CMO pools confer 
beneficial activity, in what quantity are they required, 
for how long should they be administered, and can pro-
duction on a large scale be cost-effective?
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